A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of

Ivana Ticha1, Jan Hojny2, Romana Michalkova2

  • 1Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. ivana.ticha@vfn.cz.

Scientific Reports
|November 21, 2019
PubMed

Insights

This study analyzed mutations in common melanoma types, identifying novel TP53 mutations and frequently altered genes in pathways like MAPK. Comprehensive molecular testing may guide future melanoma treatment decisions.

Area of Science:

  • Oncology
  • Genetics
  • Dermatology

Background:

  • Cutaneous melanoma, particularly superficial spreading and nodular subtypes, harbors a complex mutational landscape.
  • Understanding the full spectrum of somatic mutations and potential therapeutic targets is crucial for effective treatment.

Purpose of the Study:

  • To identify driver mutations and druggable targets in primary nodular and superficial spreading melanomas.
  • To characterize the spectrum and frequency of pathogenic variants in key cancer-related genes.

Main Methods:

  • Next-generation sequencing (NGS) using sequence capture on 114 primary melanomas.
  • Biostatistical, immunohistochemical, and functional analyses to identify driver mutations.
  • Evaluation of variants across 54 genes.

Main Results:

  • Identified 59 novel mutations, including TP53 loss-of-function mutations p.(L194P) and p.(R280K).
  • Frequently mutated genes involved MAPK pathway, chromatin remodeling, and cell cycle regulation.
  • Detected aberrations in DNA repair, tight junction regulation, and identified KDR and MET as potential targets.

Conclusions:

  • Complex molecular profiling, beyond BRAF testing, is essential for personalized melanoma treatment.
  • Newly identified mutations and pathways offer potential therapeutic avenues for cutaneous melanoma.